ClinicalTrials.gg
Not yet recruitingNCT07679984Updated Nov 12, 2026

Evaluating the Effects of a Mindfulness Intervention on Health Outcomes in Individuals With Hypertension

An interventional study of Mindfulness in Motion in Hypertension and Essential (Primary) Hypertension, sponsored by Ohio State University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Ohio State University · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 12, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Hypertension by Ohio State University — 1 open to participants now, 2 under way, none of them phase 3. Hypertension · Ohio State University.

Started
2027
the only one that year
No phase
8 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Hypertension by Ohio State University, this one is the only one that started in 2027, is one of 8 with no phase, and was the 12th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 12 studies in Hypertension by Ohio State University is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Hypertension by Ohio State University, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness of adding the Mindfulness in Motion (MIM) program to usual primary care for people with high blood pressure. MIM is a facilitated, 8-week online program that teaches simple ways to manage stress using mindfulness practices. The program also includes the use of a companion smartphone app throughout the 12-month study period. In this study, investigators will compare people who receive their usual care and take part in the MIM program with those who receive usual care alone to see if it helps improve blood pressure, weight, stress, sleep, and overall well-being. Over 12 months, participants will be asked to complete short questionnaires about stress, sleep, and resilience four times via a smartphone, tablet, or computer.

Read the detailed description

Hypertension is a major modifiable risk factor for cardiovascular disease, and effective blood pressure reduction significantly reduces the risk of stroke, myocardial infarction, and heart failure. Current clinical treatment guidelines prioritize lifestyle modification as first-line therapy for a diagnosis of hypertension. The American Heart Association (AHA) has acknowledged mind-body medicine approaches, specifically meditation-based practices, as potential supportive strategies for cardiovascular risk reduction among patients with cardiovascular risk factors and diagnoses. Complementary medicine includes a range of therapies aimed at supporting behavior change, stress reduction, self-management, and overall well-being. However, utilization of these practices remains relatively low among individuals with cardiovascular disease and cardiovascular risk factors, largely due to limited awareness of their potential benefits and practical barriers such as travel requirements and time commitment. The expansion of virtual and app based complementary practices has the potential to address key implementation barriers, including travel burden and scheduling constraints, while supporting scalable and sustained engagement.

Mindfulness-based practices, increasingly offered virtually and via smartphone applications, have shown promise for adults with elevated blood pressure and hypertension. Studies that have implemented mindfulness based interventions, ranging from one to 12 sessions, have reported clinically significant reductions in systolic and diastolic blood pressure, as well as improvements in related psychosocial outcomes such as stress, anxiety, and depression. Emerging evidence suggests that blood pressure improvements are, in part, affected by lifestyle behaviors, including improved dietary choices, medication adherence, and decreased stress.

For over two decades, Mindfulness in Motion (MIM), has been studied as an educational, community-based 8-week program that has shown significant improvements in psychosocial outcomes, such as burnout, stress, and resiliency for healthcare professionals, persons with multiple sclerosis, cancer survivors, inner-city children under economic stress, college students, and community first responders. The purpose of this study is to evaluate the effectiveness of Mindfulness in Motion (MIM), an evidence-based mindfulness intervention delivered virtually and supported by a companion smartphone application, among patients diagnosed with hypertension, compared with usual care. Individual outcomes will be assessed at four time points: baseline, at the conclusion of the 8 week virtual MIM intervention (2 month assessment), at four months following completion of the virtual 8-week intervention (6 month assessment) and again at 10 months following completion of the virtual 8-week intervention (12 month assessment). Individual outcomes will include self report measures of perceived stress, resilience, and sleep. Physiological outcome measures including body mass index (BMI), and systolic and diastolic blood pressure will be collected at baseline and again at the end of the 12-month study period. MIM attendance at the 8-weekly virtual sessions, monthly mindfulness refresher sessions, and MIM app usage, per participant per day and over the 12 month period, will be measured.

03

Conditions studied

  • Hypertension
  • Essential (Primary) Hypertension

Keywords

  • hypertension
  • primary care
  • mindfulness
  • stress
  • resilience
  • sleep
  • blood pressure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >18 years old.
  2. Established patient at OSU Family Medicine
  3. Diagnosis of primary essential hypertension
  4. Ability and willingness to participate in all Mindfulness in Motion (MIM) study activities.
  5. Ability and willingness to download MyCap, the smartphone app that securely links participant study responses to the REDCap study project.
  6. WiFi connectivity or LTE to allow use of MIM smartphone app and MyCap when not at OSU clinical site.

Exclusion criteria

Exclusion Criteria:

  1. Inability to read and/or understand English (MIM intervention, study consent and questionnaires in English).
  2. Established mindfulness practice.
  3. Diagnosis of secondary hypertension with identifiable underlying causes including:

    • Chronic kidney disease
    • Renal artery stenosis
    • Primary aldosteronism
    • Cushing's syndrome
    • Pheochromocytoma
    • Obstructive sleep apnea
    • Medication induced hypertension (e.g., , NSAIDs)
    • Pregnancy related hypertension
  4. Current severe alcohol or substance abuse disorder.
  5. Participants with documented cognitive disorder that limits the ability to independently participate in MIM program, read, understand, and/or complete the surveys; i.e. dementia, Alzheimer's or biological tests.
  6. Participants with major psychiatric disorders not controlled by medication or other psychiatric treatments.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Mindfulness in Motion plus Usual Care (Intervention Group)

    Behavioral: Mindfulness in Motion

  • No intervention
    Usual Care (Control Group)

Interventions

  • BehavioralMindfulness in Motion

    Mindfulness in Motion (MIM) is an 8-week evidence-based program designed as an intervention to help participants learn practical burnout/stress reduction and resiliency building techniques. Delivered in a virtual, synchronous group format one hour per week, MIM includes didactic instruction, community-building group discussion, mindfulness, and gentle yoga. Each session focuses on a specific theme with topics that include Willingness to Daily Practice, Cultivating Mindful Sleep, Vision of Self, Supported by the Breath, Mindful Eating and Yoga, Movement Through Balance, Awareness of Sensation, Clarity and Release, and Staying Grounded \& Moving Forward. Participants are highly encouraged to engage in 10-20 minutes of individual self-practice at least five times per week. A companion MIM smartphone app offers daily mindfulness, movement, and reflective practices.

06

What researchers measure

Primary outcomes

  1. Systolic and Diastolic Blood Pressure

    Blood pressure, obtained at each Family Medicine ambulatory appointment, is the force exerted by circulating blood against the walls of blood vessels due to heart's pumping action. It is measured in mmHg. The upper number is the measurement during the heartbeat (systolic) and the lower number is while the heart is at rest (diastolic). In the office, this measurement will be taken manually by trained medical assistants using GE Healthcare CRITIKON DURA-CUF reusable cuff and 767-Series wall/mobile sphygmomanometer in clinic and recorded in the patient's electronic medical record.

    Time frame: At baseline and at the end of the 12-month study

  2. Height/Weight_BMI

    Body Mass Index (BMI) is an auto calculation in the electronic medical record reflecting the indirect measure of body fat derived by dividing weight in kilograms by height in meters, squared. For adults 20 years of age and older, a BMI below 18.5 is considered underweight, a BMI between 18.5 and 24.9 is considered a healthy weight, a BMI of 25.0 to 29.9 is defined as overweight, and a BMI greater than 30.0 is defined as obesity.

    Time frame: At baseline and at the end of the 12-month study period

Secondary outcomes

  1. Perceived Stress Scale-10

    The Perceived Stress Scale-10 (PSS-10) is a 10-item self-report measure of perceived stress. It is a measure of the degree to which situations in one's life are appraised as stressful over the past month. The 4-point Likert Scale includes responses of 0 (never), 1 (almost never), 2 (sometimes), 3 (fairly often), and 4 (very often). Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress.

    Time frame: At baseline, at 2-months, 6-months, and at the end of the 12-month study period.

  2. Connor-Davidson Resilience Scale-10

    The Connor-Davidson Resilience Scale-10 (CD-RISC-10) is a 10-item self-report assessment of a person's ability to bounce back after adversity. A 5-point Likert Scale for each statement ranges from 0 (Not True at All), 1 (Rarely True), 2 (Sometimes True), 3 (Often True), 4 (True Nearly All of the Time). A respondent's total score can range from 0 to 40 with higher scores indicating higher resilience.

    Time frame: At baseline, 2-month assessment, 6-month assessment, and at end of the 12-month study period.

  3. PROMIS Sleep Disturbance Scale

    The PROMIS Sleep Disturbance Scale (SDS) scale is a standardized, self reported measure designed to assess perceived sleep quality and difficulty. The 8-item short form evaluates sleep impairment over the past 7 days; question responses are formatted on a 5-point Likert scale ranges from 1 (Not at all) to 5 (Very Much). Participant raw scores can range from 6 to 30 with higher scores indicating increased sleep disturbance.

    Time frame: At baseline, 2-month assessment, 6-month assessment, and at the end of the 12-month study period.

Other outcomes

  1. Mindfulness in Motion Attendance

    Intervention Group percentage of attendance of the 8-weekly virtual sessions.

    Time frame: At the end of the 12-month study period

  2. Mindfulness in Motion App Usage total time per 12-month study period

    Intervention group Mindfulness in Motion app usage, total time over 12 months in minutes/hours per participant.

    Time frame: At the end of the 12-month study period.

  3. Mindfulness in Motion mean app usage per day

    Intervention group Mindfulness in Motion app usage, mean per day per participant in minutes.

    Time frame: At the end of the 12-month study period.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2027; primary completion for Mar 2028, 12 months later.

Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 12 months is below that.

Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start Oct 2026 → Mar 2027, primary completion Oct 2027 → Mar 2028 and completion May 2028 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jul 1, 2026
StartEst.
Mar 1, 2027was Oct 2026
Primary completionEst.
Mar 1, 2028was Oct 2027
CompletionEst.
Dec 1, 2028was May 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Mar 1, 2027
Nov 12, 2026
Primary completion
Oct 1, 2027→Mar 1, 2028
Nov 12, 2026
Study completion
May 1, 2028→Dec 1, 2028
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Start date Oct 1, 2026→Mar 1, 2027
    Primary completion Oct 1, 2027→Mar 1, 2028
    Study completion May 1, 2028→Dec 1, 2028

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07679984
Responsible party
Beth Steinberg (Associate Director of Research, Ohio State University) — Principal investigator
First posted
Jul 1, 2026
Start date
Mar 1, 2027 (estimated)
Primary completion
Mar 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Beth Steinberg, PhD, RN
Contact
beth.steinberg@osumc.edu
614-406-7067

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion